Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...
Medscape18d
Preoperative Administration of Epoetin alfa to Reduce Transfusion Requirements in Elderly Patients Having Primary Total Hip or Knee Reconstruction
We conducted a study comparing the safety and efficacy of preoperative recombinant human erythropoietin (epoetin alfa) in patients having major elective orthopaedic surgery and in matched ...
Medscape23d
Every-Three-Week Administration of Darbepoetin Alfa in Women With Chemotherapy-Associated Anemia
Study patients received subcutaneous darbepoetin alfa 6.75 ... Although they are effective, thrice-weekly or weekly regimens of epoetin alfa can pose an economic burden on patients with persistent ...
The Financial Times26d
Russian billionaires Fridman and Aven sell Alfa-Bank stakes in bid to overturn sanctions
Fridman and Aven offloaded Alfa-Bank and Alfa Strakhovanie to their longtime partner Andrei Kosogov last year, according to documents seen by the Financial Times, completing a deal struck in 2023 ...
Finanznachrichten27d
Amgen Reports Fourth Quarter And Full Year 2024 Financial Results
THOUSAND OAKS, Calif., Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023. "Robust ...
The American Journal of Managed Care28d
FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease
Onapgo, a subcutaneous apomorphine infusion device, is approved for advanced Parkinson's disease, offering continuous symptom management without surgery. The TOLEDO trial showed apomorphine ...